News | July 03, 2024
LG Chem enters Chinese osteoarthritis treatment market
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Imfinzi also recommended for patients with mismatch repair deficient disease
Renews GMP certifications for India and Malaysia sites
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Subscribe To Our Newsletter & Stay Updated
